were among the worst-performing health-related stocks Wednesday, falling 9% after the company reiterated its 2005 earnings projection but lowered its sales estimate.
The health care ratings company continues to see earnings at the high end of its previous guidance of 10 cents to 13 cents a share, but sales growth is now seen at slightly lower than 45%, which is below the company's previous guidance of 45% to 55%.
For 2006, the company expects an operating margin of about 25% on sales growth of at least 40% over 2005 results. Shares recently were trading down 59 cents to $6.
(WBMD - Get Report)
fell 4% after the provider of health information services said it acquired eMedicine.com for $25.5 million. eMedicine.com, an online publisher of medical information, had break-even earnings and about $6 million in revenue during 2005. "The acquisition of eMedicine.com complements WebMD's current offerings for physicians and health care professionals," WebMD said in a statement. WebMD expects the deal to add to 2006 earnings before interest, taxes, depreciation, amortization, but it will be offset by integration-related costs. The company's shares recently were down $1.51 to $37.49.
(AET - Get Report)
shares rose 4% after the health insurance company named a new chief medical officer and was upgraded by J.P. Morgan. The company named Troyen Brennan chief medical officer to take over for Charles Cutler, who had been serving as interim medical chief. Brennan, who joins Aetna Feb. 21, is a professor of medicine at Harvard Medical School and also served as president and CEO of Brigham & Women's Physicians Organization.
Separately, J.P. Morgan upgraded Aetna to overweight from neutral. Aetna shares rose $3.67 to $92.88.
traded actively after the medical device company said
(BSX - Get Report)
most recent $27 billion buyout offer is superior to
Johnson & Johnson's
$24 billion offer. Guidant, which already signed a merger agreement with Johnson & Johnson, now must wait five business days, or until Jan. 25, before changing its recommendation or ending the Johnson & Johnson deal, which is worth $71 a share, and agree to Boston Scientific's offer, valued at $80 a share.